Rock bottom interest rates will likely boost key stocks in the biotechnology sector, but Obamacare will dampen prospects for HMO shares.
TheStreet.com offers up 13 biotech predictions for 2013.
Oct 12- AEterna Zentaris Inc:. *Announces pricing of US $16.5 million public offering of common shares and. *Says public offering of 6.6 million units priced at $2.50/ unit.
NEW YORK-- Canadian drugmaker Aeterna Zentaris Inc. said Friday it is selling 6.6 million units of stock and warrants to raise money for product development. Shares of Aeterna Zentaris lost 73 cents, or 23.4 percent, to $2.39 in midday trading.
NEW YORK-- Canadian drugmaker Aeterna Zentaris Inc. said Wednesday that it will conduct a six-for-one reverse stock split to boost its share price and regain compliance with Nasdaq rules.
Oct 3- AEterna Zentaris Inc:. *Announces share consolidation to regain NASDAQ compliance. basis on October 5, 2012.
Here are some snap biotech and drug stock judgments after a weekend spent at the American Society of Clinical Oncology annual meeting.
The bulls were all over Keryx Biopharmaceuticals and AEterna Zentaris Monday amid optimism about their Perifosine drug.